New Latin American Edition of NCCN Guidelines® Available
By Jonathan Larsen, MPP, Manager, Global Business Development
The National Comprehensive Cancer Network® (NCCN®) has published a new Latin American Edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma in both Portuguese and Spanish on NCCN.org and the Virtual Library of NCCN Guidelines® app, available for iPhones and Android™ Smartphones.
This Latin American Edition is the result of the second annual International Day held on 16 March 2014 in conjunction with the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™. During the conference, hematologists from Latin America came to Hollywood, Florida to attend conference sessions and to meet with NCCN Guidelines® Panel members and NCCN staff to discuss the consideration of a regional adaptation of the NCCN Guidelines for Multiple Myeloma necessary for effective utilization of the guidelines in the region.
Regarding the regional adaptation process, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Chair, NCCN Multiple Myeloma Guidelines Panel, noted, “It is a unique opportunity both personally and professionally to work with our colleagues in Latin America to improve current medical practice and improve patient access to novel therapies.”
“I have had an exceptional experience,” said Dorotea Fantl, MD, Chief of Hematology at the Hospital Italiano de Buenos Aires, Argentina, “We discussed the way we treat our patients, as well as the current health care regulatory environment in our respective countries. I look forward to continuing collaborations with friends and colleagues.”
“The NCCN Guidelines for Multiple Myeloma are very important and useful for clinical practice, as they address appropriate management options. Regional adaptations optimally provide for necessary local adjustment to these guidelines,” reflected Vania Hungria, MD, PhD, Santa Casa Medical School, São Paulo, Brazil, “I believe that these modifications will make these guidelines more realistic for local use. This is a win-win situation for the patient!”
Clinical participants in the second annual International Day included Dr. Anderson; William Bensinger, MD, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Vice-Chair, NCCN Multiple Myeloma Guidelines Panel; Vania Hungria, MD, PhD, Santa Casa Medical School, São Paulo, Brazil; Dorotea Fantl, MD, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Gustavo Milone, MD, FUNDALEU, Buenos Aires, Argentina; and Angelo Maiolino, MD, PhD, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Nearly half of all registered users of the NCCN Guidelines on NCCN.org report that they live outside the United States. NCCN regularly works with thought leaders throughout the world to review the NCCN Guidelines with consideration of metabolic differences in populations, local accessibility, and regulatory status of health care technologies used in cancer care in the specified country. The resulting foreign editions, regional adaptations, and consensus statements of the NCCN Guidelines are considered NCCN Guidelines derivatives. The modified NCCN Guidelines are then translated into the local language with specified modifications, published on NCCN.org, and distributed locally to aid clinicians in determining appropriate and effective cancer care. An article detailing the regional adaptation process was published in the May issue of JNCCN (J Natl Compr Canc Netw 2014;12:643–648).1
For additional information on NCCN International Programs, visit NCCN.org/international. To learn more about international programming opportunities, please contact Marisa Getzewich, Manager, Business Development, at firstname.lastname@example.org.
Permission for use and/or distribution the NCCN Guidelines globally can be requested here: http://www.nccn.org/about/permissions/
1 Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB, Anderson BO. International adaptations of NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2014;12:643–648.
Apple is a trademark of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
Google Play is a trademark of Google Inc. Android is a registered trademark of Google.